Navigation Links
Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
Date:6/21/2012

SUNNYVALE, Calif., June 21, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced that the Company was featured in BioWorld Today, Brewer Sports' 2nd Annual Sports Law and CLE Symposium and Opportunist Magazine.

On June 15th, 2012, a featured article on Amarantus was published in the NewCo News section of BioWorld Today entitled "Amarantus Restart Makes another Run at MANF Protein" and is available at http://www.bioworld.com/content/amarantus-restart-makes-another-run-manf-protein.

On Thursday, June 14th, 2012, Amarantus President & CEO Gerald Commissiong attended the Brewer Sports 2nd Annual Sports Law and CLE Symposium in Minneapolis, MN, and appeared as the biotherapeutics/athlete representative on a panel discussing the scientific, medical, legal, social and moral issues surrounding the emerging debate on how amateur and professional sports leagues should cope with the short-term and long-term impact of concussions and TBI. Other panelists included Dr. Bruce Leuchter, Associate Professor of Psychiatry at Cornell Medical College, Ross Bernstein author of "The Code: Football's Unwritten Rules and Its Ignore-at-Your-Own-Risk Code of Honor"  and Michael Hausfeld, Lead Counsel for the NFL's retired players in their class-action lawsuit against the NFL.

On June 12th, 2012, Amarantus President & CEO Gerald Commissiong appeared on the cover of Opportunist Magazine, online at http://opportunistmagazine.com/gerald-commissiong-name/.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

 

MEDIA CONTACT:
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408.737.2734 x 102
pr@amarantus.com


'/>"/>
SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Entia Biosciences Receives Patent for Use of Ergothioneine in Foods and Beverages
3. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
4. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
5. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
6. Sangamo BioSciences Reports First Quarter 2012 Financial Results
7. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
8. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
9. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
10. IntelliCell BioSciences Expands Management Team
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... , ... October 09, 2017 , ... ... four-tiered line of medical marijuana products targeting the needs of consumers who are ... of Kindred takes place in Phoenix, Arizona. , As operators of two successful ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):